Skip to main content

Table 1 Descriptive characteristics of GENOA African Americans

From: Intrinsic and extrinsic epigenetic age acceleration are associated with hypertensive target organ damage in older African Americans

Characteristic Non-Missing N Mean (SD) or %
Age at Phase I (years) 1390 58.0 (10.1)
DNAm age at Phase I (years) 1390 55.0 (9.9)
IEAA 1389 0.1 (4.8)
EEAA 1390 0.2 (5.8)
Time between Phases I and II 1390 5.1 (1.3)
Sex 1390  
 Male   28.9%
 Female   71.1%
Smoking 1390  
 Never   60.2%
 Former   27.6%
 Current   12.2%
BMI (kg/m2) 1390 31.7 (6.7)
Systolic BP (mmHg) 1390 138.5 (20.8)
Diastolic BP (mmHg) 1390 79.5 (10.9)
Antihypertensive use 1390  
 No   29.2%
 Yes   70.8%
Diabetes 1390  
 No   69.7%
 Yes   30.3%
Albuminuria (mg/g) 1390  
 Normal   81.7%
 Microa   14.3%
 Macrob   4.0%
eGFR (mL/min/1.73m2) 1390 88.9 (21.0)
UACR (mg/g) 1390 68.4 (352.9)
RWT 1352 0.3 (0.1)
LVMI (g/m2.7) 1346 39.3 (10.4)
ABI 1359 1.0 (0.1)
WMH (cm3)c 758 10.6 (11.6)
TIV (cm3)c 766 1373.9 (135.8)
  1. Abbreviations: IEAA Intrinsic epigenetic age acceleration, EEAA Extrinsic epigenetic age acceleration, BMI Body mass index, BP Blood pressure, TIV Total intracranial volume, eGFR Estimated glomerular filtration rate, UACR Urinary albumin to creatinine ratio, LVMI Left ventricular mass index, RWT Relative wall thickness, ABI Ankle-brachial index, WMH White matter hyperintensity, TIV Total intracranial volume
  2. aMicroalbuminuria is defined as 30 mg/g ≤ UACR < 300 mg/g
  3. bMacroalbuminuria is defined as UACR ≥300 mg/g
  4. cWMH and TIV were measured an average of 6.3 years after Phase I
  5. All measures were taken at Phase II unless otherwise noted